Medtide (FRA:FQ2) NonCurrent Deferred Liabilities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FQ2 Medtide Inc FRA:FQ2
31 GF Score
Price €2.18
View Full Analysis

What is Medtide NonCurrent Deferred Liabilities?

Medtide FRA:FQ2 -6.03% 31 NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:FQ2 with a GF Score™ of 31/100.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Medtide's non-current deferred liabilities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Medtide NonCurrent Deferred Liabilities Related Terms

Medtide NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Medtide's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtide NonCurrent Deferred Liabilities Chart

Medtide Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
0.00 0.00 0.00 0.00 0.00

Medtide Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:FQ2
31GF Score
Medtide Inc FRA:FQ2
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
Medtide (FRA:FQ2) has a NonCurrent Deferred Liabilities of €0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Medtide and its competitors.
Is Medtide's NonCurrent Deferred Liabilities too high?
Medtide's current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, Medtide has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Medtide's NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Medtide and its competitors. Medtide's current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (FRA:FQ2) has a current NonCurrent Deferred Liabilities of €0.00 Mil. The current NonCurrent Deferred Liabilities is €0.00 Mil. Medtide's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Medtide (FRA:FQ2), the current NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medtide Business Description

Other Exchanges 03880:Hong Kong
Address No. 69, 12 Street, Qiantang District, Zhejiang, Hangzhou, CHN
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score

Get the complete analysis for FRA:FQ2

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.18
Price